- Home
- REVBW vs MWA Comparison
REVBW vs MWA Comparison
Compare REVBW & MWA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- MWA
- Stock Information
- Founded
- REVBW N/A
- MWA 1857
- Country
- REVBW United States
- MWA United States
- Employees
- REVBW 9
- MWA N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- MWA Metal Fabrications
- Sector
- REVBW Health Care
- MWA Industrials
- Exchange
- REVBW Nasdaq
- MWA Nasdaq
- Market Cap
- REVBW N/A
- MWA N/A
- IPO Year
- REVBW 2020
- MWA 2006
- Fundamental
- Price
- REVBW $0.01
- MWA $24.30
- Analyst Decision
- REVBW
- MWA Hold
- Analyst Count
- REVBW 0
- MWA 5
- Target Price
- REVBW N/A
- MWA $22.20
- AVG Volume (30 Days)
- REVBW N/A
- MWA 1.2M
- Earning Date
- REVBW N/A
- MWA 11-06-2024
- Dividend Yield
- REVBW N/A
- MWA 1.10%
- EPS Growth
- REVBW N/A
- MWA 35.28
- EPS
- REVBW N/A
- MWA 0.74
- Revenue
- REVBW N/A
- MWA $1,314,700,000.00
- Revenue This Year
- REVBW N/A
- MWA $3.98
- Revenue Next Year
- REVBW N/A
- MWA $5.34
- P/E Ratio
- REVBW N/A
- MWA $32.85
- Revenue Growth
- REVBW N/A
- MWA 3.06
- 52 Week Low
- REVBW N/A
- MWA $13.08
- 52 Week High
- REVBW N/A
- MWA $26.28
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- MWA 60.34
- Support Level
- REVBW N/A
- MWA $23.23
- Resistance Level
- REVBW N/A
- MWA $26.28
- Average True Range (ATR)
- REVBW 0.00
- MWA 0.70
- MACD
- REVBW 0.00
- MWA 0.14
- Stochastic Oscillator
- REVBW 0.00
- MWA 58.58
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).